Powrót do Strony Głównej | Kalendarium

pl
Miejsce:
Online
Data:
06.10 - 08.10 / 2022

15th International Cardiovascular Reasearch Meeting

Konferencja pod patronatem Oddziału Bydgoskiego Polskiego Towarzystwa Kardiologicznego

Do wydarzenia pozostało:
0 Dni 0 Godzin 0 Minut 0 Sekund
pl

Transmisja Live

Szanowni Państwo!

W tym miejscu po zarejestrowaniu na Wydarzenie oraz zalogowaniu na Konto Użytkownika będzie dostępne okno transmisji.

Transmisja zostanie udostępniona w tym miejscu 20 minut przed planowym rozpoczęciem wydarzenia.

PROGRAM MERYTORYCZNY

Zapraszamy do zapoznania się ze szczegółami programu.

09:00 - 09:05
Opening speech

Jacek Kubica (PL)

09:05 - 09:25
Opening Lecture - How to optimise antithrombotic therapy in cardiogenic shock?

Diana A. Gorog (UK)

09:25 - 09:30
Break
09:30 - 11:30
SESSION 1
09:30 - 09:45
Predictors of in-hospital clinical outcome in COVID-19 patients

Leszek Gromadziński (PL)

09:45 - 10:00
Determinants of anti-SARS-CoV-2 antibodies after vaccination

Magdalena Krintus (PL)

10:00 - 10:15
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study

Przemysław Podhajski (PL)

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study
10:15 - 10:30
Metformin use in patients hospitalized with COVID-19

Paul A. Gurbel (USA)

10:30 - 10:45
IMPACT of PCSK9 inhibition on clinical outcome in patients with COVID-19 (The IMPACT COVID 19 - SIRIO 5 randomized study)

Eliano P. Navarese (IT)

10:45 - 11:00
Post-COVID-19 rehabilitation

Małgorzata Ostrowska (PL)

11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 2
11:45 - 12:00
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor

Piotr Niezgoda (PL)

12:00 - 12:05
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor. A Contrarian View

Wiktor Kuliczkowski (PL)

12:15 - 12:30
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor

Piotr Adamski (PL)

12:30 - 12:45
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor. A Contrarian View

Michael Savage (USA)

12:45 - 13:00
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – a Metaanalysis

Eliano P. Navarese (IT)

13:00 - 13:15
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – the PL- ACS Registry

Jacek Kubica (PL)

13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:00
SESSION 3
14:00 - 14:15
Use of ultra-thin strut sirolimus-eluting coronary stents in acute coronary syndrome – is it a way to reduce risk of throbosis?

Tommaso Gori (D)

14:15 - 14:30
Pharmacodynamics of cangrelor in cardiogenic shock – clinical implications

Jolanta Siller-Matula (A)

14:30 - 14:45
Diurnal variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor

Piotr Adamski (PL)

14:45 - 15:00
Is personalized pharmacotherapeutic approach closed for acute coronary syndrome?

Udaya Tantry (USA)

15:00 - 15:15
Prasugrel or ticagrelor in acute coronary syndrome – is a tailored choice justified? – the PL-ACS registry

Jacek Kubica (PL)

15:15 - 15:30
Microcirculation assessment in patients with acute coronary syndrome undergoing PCI

Jacek Legutko (PL)

15:30 - 16:00
DISCUSSION
16:00 - 16:15
Break
16:15 - 18:00
SESSION 4 - Young Researchers Session: COVID-19 - a Challenge for the Healthcare System
09:00 - 09:20
The role of ACE-inhibitors in cardiovascular continuum: focus on the SMILE project

Claudio Borghi (IT)

09:20 - 09:30
Break
09:30 - 11:30
SESSION 5
09:30 - 09:45
Impact of COVID-19 pandemic on out-of- hospital cardiac arrest occurence (OSCAR-POL registry)

Jakub Ratajczak (PL)

09:45 - 10:00
Epidemiology, management and survival rate of out-of-hospital cardiac arrest

Klaudiusz Nadolny (PL)

10:00 - 10:15
Imapct of therapeutic hypothermia after a sudden cardiac arrest in patients with myocardial infarction

Agata Sobczyk (PL)

10:15 - 10:30
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia

Marek T. Tomala (PL)

10:30 - 10:45
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (UNICORN study)

Julia M. Umińska (PL)

10:45 - 11:00
Stent thrombosis in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (ST-OHCA study)

Martin Rauber (SLO)

11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 6
11:45 - 12:00
Recombinant Human Lecithin Cholesterol Acyl transferase in Acute ST-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Marc Bonaca (USA)

12:00 - 12:15
Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention in patients with prior CABG (The TWILIGHT-CABG study)

Robert Gil (PL)

12:15 - 12:30
Low-dose prasugrel or clopidogrel for elderly patients with acute coronary syndrome? (A sub-study of the ELDERLY ACS 2 trial)

Stefano De Servi (IT)

12:30 - 12:45
Revascularization in STEMI patients with multi-vessel disease (multicenter registry)

Wojciech Wojakowski (PL)

12:45 - 13:00
New insights from an old study - results from the PLATelet inhibition and patients Outcomes (PLATO) trial

Andrzej Budaj (PL)

13:00 - 13:15
PCI versus CABG for treatind in-stent restenosis in unprotected left main (LM-DRAGON registry)

Wojciech Wańha (PL)

13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:05
SESSION 7
14:00 - 14:15
Virtual reality-enhanced rehabilitation in patients with coronary artery disease

Robert Gajda (PL)

14:15 - 14:30
Early standardized clinical judgement for syncope diagnosis in the emergency department

Salvatore di Somma (IT)

14:30 - 14:45
Efficacy and safety of CSK9 inhibitors in patients with familial hypercholesterolemia – an observational study

Krzysztof Chlebus (PL)

14:45 - 15:00
Management and predictors of clinical events in 75 686 patients with acute myocardial infarction

Piotr Jankowski (PL)

15:00 - 15:15
The role of miRNAs in regulation of platelet activity

Marek Postuła (PL)

15:15 - 15:30
Impact of levosimendan on clinical outcome in patients with takotsubo syndrome

Miłosz Jaguszewski (PL)

15:30 - 16:00
DISCUSSION
16:00 - 16:05
Closing remarks

Jacek Kubica (PL)

16:05 - 16:15
Break
16:15 - 18:00
SESSION 8 - ELECTRA-SIRIO 2 trial investigators meeting
09:00 - 13:00
ELECTRA-SIRIO 2 trial investigators meeting

Pliki do pobrania

Certyfikat INFARMA

PARTNERZY KONFERENCJI

OPCJE REJESTRACJI

Rejestracja poprzez konto na stronie jest obowiązkowa dla uczestnictwa w spotkaniu.

Wybór pakietu (ROZWIŃ LISTĘ PONIŻEJ):

Opłaty konferencyjne:

Zarejestruj się

Kontakt

Kontakt w sprawie
Problemów Technicznych
Krzysztof Sęk

Organizatorem logistycznym konferencji jest Grupa Gran
ul. Generała Tadeusza Bora-Komorowskiego 35, 85-793 Bydgoszcz